Revvity Inc. (NYSE:RVTY) Holdings Decreased by Bessemer Group Inc.

Bessemer Group Inc. decreased its holdings in Revvity Inc. (NYSE:RVTY - Free Report) by 56.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,288 shares of the company's stock after selling 19,866 shares during the quarter. Bessemer Group Inc.'s holdings in Revvity were worth $1,618,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RVTY. T. Rowe Price Investment Management Inc. grew its holdings in Revvity by 16.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 20,761,308 shares of the company's stock valued at $2,317,170,000 after purchasing an additional 2,969,326 shares during the period. EdgePoint Investment Group Inc. grew its stake in shares of Revvity by 51.1% during the 4th quarter. EdgePoint Investment Group Inc. now owns 4,058,231 shares of the company's stock valued at $452,939,000 after buying an additional 1,372,456 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Revvity by 17.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,631,597 shares of the company's stock worth $851,764,000 after buying an additional 1,151,821 shares during the last quarter. Norges Bank acquired a new stake in shares of Revvity during the 4th quarter worth $127,801,000. Finally, GAMMA Investing LLC raised its position in shares of Revvity by 15,023.0% in the 1st quarter. GAMMA Investing LLC now owns 287,035 shares of the company's stock worth $30,368,000 after buying an additional 285,137 shares during the period. Hedge funds and other institutional investors own 86.65% of the company's stock.

Revvity Stock Up 1.3%

Shares of NYSE:RVTY traded up $1.33 during trading on Wednesday, hitting $100.36. The company's stock had a trading volume of 411,036 shares, compared to its average volume of 965,772. The company has a market capitalization of $11.83 billion, a PE ratio of 42.75, a PEG ratio of 2.44 and a beta of 0.98. Revvity Inc. has a fifty-two week low of $87.70 and a fifty-two week high of $129.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.99 and a current ratio of 3.58. The stock's 50-day moving average price is $93.64 and its two-hundred day moving average price is $105.12.

Revvity (NYSE:RVTY - Get Free Report) last announced its earnings results on Monday, April 28th. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.96 by $0.05. Revvity had a return on equity of 7.73% and a net margin of 10.35%. The company had revenue of $664.76 million for the quarter, compared to analyst estimates of $662.30 million. During the same period in the prior year, the company posted $0.98 EPS. Revvity's quarterly revenue was up 2.3% on a year-over-year basis. As a group, sell-side analysts expect that Revvity Inc. will post 4.94 EPS for the current year.

Revvity Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 8th. Shareholders of record on Friday, July 18th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.28%. The ex-dividend date is Friday, July 18th. Revvity's dividend payout ratio is currently 11.91%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on RVTY shares. JPMorgan Chase & Co. lowered their price target on Revvity from $120.00 to $100.00 and set a "neutral" rating for the company in a research report on Tuesday, April 29th. Bank of America dropped their target price on shares of Revvity from $116.00 to $110.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. UBS Group raised shares of Revvity from a "neutral" rating to a "buy" rating and reduced their price target for the company from $145.00 to $115.00 in a research report on Thursday, May 1st. Wells Fargo & Company dropped their price objective on shares of Revvity from $130.00 to $102.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Finally, Robert W. Baird cut their target price on shares of Revvity from $127.00 to $125.00 and set an "outperform" rating on the stock in a research note on Tuesday, April 29th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $123.64.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.